Chrystal Jensen Sells 30,845 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) insider Chrystal Jensen sold 30,845 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $2.01, for a total transaction of $61,998.45. Following the transaction, the insider owned 1,059,139 shares in the company, valued at approximately $2,128,869.39. This trade represents a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cerus Trading Down 8.3%

NASDAQ:CERS opened at $1.77 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. The firm has a market cap of $340.14 million, a price-to-earnings ratio of -22.13 and a beta of 1.51. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.96. The firm has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $1.86.

Cerus (NASDAQ:CERS) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The firm had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%. On average, equities analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CERS has been the topic of a number of recent analyst reports. TD Cowen reiterated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Institutional Trading of Cerus

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Cerus by 0.6% in the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after buying an additional 62,663 shares during the period. Wasatch Advisors LP grew its stake in shares of Cerus by 2.6% during the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after acquiring an additional 213,917 shares during the period. Millennium Management LLC increased its holdings in Cerus by 17.6% in the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after acquiring an additional 519,301 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock worth $3,710,000 after acquiring an additional 733,683 shares during the last quarter. Finally, Ieq Capital LLC raised its stake in Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock valued at $4,993,000 after acquiring an additional 25,771 shares during the period. 78.37% of the stock is owned by hedge funds and other institutional investors.

Cerus News Summary

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Institutional accumulation — several hedge funds materially increased positions (AQR, Cubist, Millennium reported big additions), which provides supportive demand beneath the stock and signals some investor conviction.
• Positive Sentiment: Recent quarter: Cerus reported revenue of $64.6M versus ~$59.3M consensus, a topline beat that is constructive for fundamentals even though the company remains unprofitable.
• Neutral Sentiment: Short‑interest prints look erroneous — reported short interest shows 0 shares and 0.0 days‑to‑cover for early March; treat those figures as unreliable until exchanges correct filings.
• Neutral Sentiment: Analyst posture is mixed: one independent provider downgraded CERS to Hold recently while TD Cowen maintained a Buy earlier in January — consensus sits near “Hold,” so no clear new catalyst from Street coverage.
• Negative Sentiment: Significant insider selling across leadership — multiple insiders disclosed sales Mar. 5–9 that reduced insider stakes by low‑ to mid‑single digits (CEO William Greenman, CFO Kevin D. Green, COO Vivek Jayaraman, director Richard J. Benjamin, Chrystal Jensen). These filings increase circulating supply and likely drove negative sentiment. CEO filing: Read More.; CFO filing: Read More.; Richard Benjamin filings: Read More..

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.